publication date: Dec. 19, 2010

In this issue: 

FDA requires independent confirmation of disease progression in cooperative group trials; seeks documentation for Avastin in breast cancer.

Cancer center directors say collaboration, funding, and application of best practices will reduce the burden of cancer.

Bristol-Myers Squibb board removes CEO Peter Dolan over Plavix deal. Two Republican Senators say they will place holds on confirmation of Andrew von Eschenbach as FDA commissioner. Craig Thompson named director of Abramson Cancer Center.

Download (PDF 748KB)

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.